In Brief: Legatrin PM
This article was originally published in The Tan Sheet
Executive Summary
Legatrin PM: Columbia Labs soon plans to launch reformulated version of its Legatrin nocturnal leg cramp product. Legatrin PM does not contain quinine but does contain a combination of acetaminophen and diphenhydramine. The product will be promoted for occasional sleeplessness and muscle aches and pains such as those associated with leg cramps, the firm said. FDA banned the use of quinine in leg cramp products in an Aug. 22, 1994 final rule on the product class, effective Feb. 22 ("The Tan Sheet" Aug. 22, 1994, p. 8). Separately, FDA recently sent letters to 44 companies warning that prescription quinine can no longer be sold for leg cramps without an approved NDA or ANDA. The letters follow a Sept. 8, 1994 citizen petition from Public Citizen's Health Research Group requesting such action...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning